News
- Author:
- Sara Freeman
Publish date: December 15, 2022
Exposure to detergents, dusts, and other chemicals in the workplace could be putting genetically susceptible people at risk of rheumatoid arthritis...
News
- Author:
- Sara Freeman
Publish date: December 2, 2022
Having both hypertensive disorders and diabetes while pregnant ups later cardiovascular risk, suggesting greater care is needed when these conditio...
News
- Author:
- Sara Freeman
Publish date: November 30, 2022
Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target tr...
News
- Author:
- Sara Freeman
Publish date: October 5, 2022
ADvocate1 and ADvocate2 are two of several phase 3 trials evaluating the efficacy and safety of lebrikizumab for the treatment of atopic dermatitis...
News
- Author:
- Sara Freeman
Publish date: October 5, 2022
Ruxolitinib is a Janus kinase 1/2 inhibitor that has been available for the treatment for atopic dermatitis for more than a year.
News
- Author:
- Sara Freeman
Publish date: October 4, 2022
Treatment with the oral JAK inhibitor was significantly more effective than placebo only with the highest dose evaluated.
News
- Author:
- Sara Freeman
Publish date: September 30, 2022
“This is truly transformative therapy,” one of the investigators, Brett King, MD, PhD, said.
News
- Author:
- Sara Freeman
Publish date: September 30, 2022
"We are able to identify predictive immune biomarkers of atopic dermatitis using a noninvasive method," the investigator said.
News
- Author:
- Sara Freeman
Publish date: September 30, 2022
A significant 5.8% decrease in hepatic steatosis was seen after 24 weeks’ treatment with ezetimibe and rosuvastatin comparing baseline with end of ...
News
- Author:
- Sara Freeman
Publish date: September 23, 2022
Having a hysterectomy appears to increase the risk of incident type 2 diabetes, particularly in younger women, and if the ovaries are removed at th...
News
- Author:
- Sara Freeman
Publish date: September 22, 2022
A small increased risk of ADHD in children born to mothers with diabetes, including pregestational diabetes and gestational diabetes, has been foun...
News
- Author:
- Sara Freeman
Publish date: September 20, 2022
“In this randomized, placebo-controlled trial, oral apremilast demonstrated effectiveness and was well tolerated.”
News
- Author:
- Sara Freeman
Publish date: September 19, 2022
Research into HS is "an incredibly active field at this moment," said Alexa B. Kimball, MD, MPH.
News
- Author:
- Sara Freeman
Publish date: September 17, 2022
Drinking four cups of tea a day was linked to a 17% lower risk for developing type 2 diabetes in a study, but experts warn these data are observati...
News
- Author:
- Sara Freeman
Publish date: September 13, 2022
The study evaluated a foam formulation of roflumilast, a PDE4 inhibitor that is available for topical use in a cream formulation that was recently ...
